Evidence map›Paper›PMID 41717925›Full record

ArticleIndian dermatology online journal2026

Psychopharmacology in Dermatology.

Olivia Katamanin, Sheila Sharifi, Mohammad Jafferany

Abstract read
In one paragraph

Article in Indian dermatology online journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Skin on Drugs: Psychotropic Compounds in Cutaneous Biology.International journal of molecular sciences · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Olivia KatamaninChicago Medical School, Rosalind Franklin University, North Chicago, Illinois, USA.
Sheila SharifiDr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA.
Mohammad JafferanyDepartment of Psychiatry and Behavioral Sciences, Central Michigan University College of Medicine, Mount Pleasant, Michigan, USA.ORCID 0000-0001-6358-9068

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractPsychodermatology encompasses the complex relationship between psychiatric disorders and dermatologic conditions, focusing on their bidirectional effects. This review delves into the role of psychopharmacology in managing dermatologic diseases and their associated psychiatric comorbidities, specifically investigating how psychotropic medications, such as antidepressants, anxiolytics, and antipsychotics, are used to treat dermatologic conditions with psychiatric comorbidities and their impact on both skin health and psychiatric symptoms. A narrative review was conducted, synthesizing studies published between 2019 and 2024 that included studies focused on psychopharmacological interventions in psychocutaneous disorders. Relevant literature was analyzed to evaluate the efficacy of psychotropic medications in improving both dermatologic and psychiatric symptoms. The present review highlighted that psychotropic medications, particularly antidepressants, anxiolytics, and antipsychotics, offer significant benefits in managing psychodermatologic conditions. Across the literature, antidepressants were shown to reduce inflammation and immune dysregulation in conditions such as psoriasis and hidradenitis suppurativa. Furthermore, psychotropic drugs were shown to alleviate psychiatric symptoms associated with dermatologic diseases, such as anxiety, compulsive behaviors, and delusional thoughts. Although the literature has demonstrated the efficacy of psychotropic medication in treating dermatologic diseases, psychiatric referrals and psychopharmacological treatments remain underutilized in clinical practice. Psychopharmacology plays a crucial role in managing psychodermatologic conditions by addressing both skin and psychiatric symptoms. Despite growing evidence of the importance and utility of psychodermatology, there is a need for greater awareness and incorporation of multidisciplinary psychiatric evaluation and treatment in dermatologic care. Future research should focus on larger, longitudinal studies to assess the long-term efficacy and safety of psychotropic medications in dermatology.

Indexed as

Identifiers

PMID41717925
PMCPMC13021187

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.